The effect of pregnancy on the population pharmacokinetics of levofloxacin in South Africans with rifampicin-resistant tuberculosis
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.01626-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Sharon Sawe und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. Hauptthemen laut MEDLINE: Antitubercular Agents, Levofloxacin, Rifampin, Tuberculosis, Multidrug-Resistant. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NICHD NIH HHS.
Abstract (Originalsprache)
Levofloxacin is a key drug in the prevention and treatment of rifampicin-resistant tuberculosis (RR-TB). There are limited data describing the effect of pregnancy on the pharmacokinetics of levofloxacin. We aimed to characterize the pharmacokinetics of levofloxacin in adults with RR-TB, including the effect of pregnancy. We pooled data from two studies conducted in adult participants treated for RR-TB in South Africa. Treatment regimens in both studies included levofloxacin dosed at 750/1000 mg daily, depending on body weight. We analyzed data from 47 participants, 31 (66%) living with HIV, using nonlinear mixed-effects modeling in NONMEM v7.5.1. Out of 33 female participants, 21 were pregnant, of whom 12 contributed matched antepartum and postpartum pharmacokinetic profiles. Levofloxacin followed one-compartment pharmacokinetics with first-order elimination and absorption with transit absorption compartments. The clearance and volume of distribution for a typical non-pregnant participant (weight: 58 kg; age: 32 years; serum creatinine: 56.2 µmol/L) were 6.06 (95% confidence interval [CI], 5.47 to 6.53) L/h and 85.9 (95% CI, 80.6 to 91.7) L, respectively. Higher serum creatinine levels were associated with lower levofloxacin clearance using a power function with an exponent of −0.367 (95% CI, −0.493 to −0.104). Pregnancy increased levofloxacin clearance by 38.1% (95% CI, 23.4% to 57.1%), with substantially lower exposures in pregnant compared with non-pregnant participants receiving equivalent weight-based doses. To achieve non-pregnant equivalent exposures of levofloxacin, an additional 250 mg tablet may be required, although further study is needed to assess the safety implications of a higher recommended dose in pregnant women.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
- Department of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa.
- HIV and Other Infectious Diseases Research Unit (HIDRU), South African Medical Research Council, Durban, South Africa.
ORCID-Profile: Sharon Sawe, Lubbe Wiesner, Gary Maartens, Paolo Denti
Förderung
- NIAID NIH HHS
- NICHD NIH HHS
Zitieren
APA
Sawe, S., Tsirizani, L., Court, R., Gausi, K., Poswa, A., Badat, T., Wiesner, L., Loveday, M., Maartens, G., Conradie, F., & Denti, P. (2025). The effect of pregnancy on the population pharmacokinetics of levofloxacin in South Africans with rifampicin-resistant tuberculosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01626-24
Vancouver
Sawe S, Tsirizani L, Court R, Gausi K, Poswa A, Badat T, et al. The effect of pregnancy on the population pharmacokinetics of levofloxacin in South Africans with rifampicin-resistant tuberculosis. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01626-24
BibTeX
@article{Sawe2025,
author = {Sawe, Sharon and Tsirizani, Lufina and Court, Richard and Gausi, Kamunkhwala and Poswa, Asanda and Badat, Tasnim and Wiesner, Lubbe and Loveday, Marian and Maartens, Gary and Conradie, Francesca and Denti, Paolo},
title = {The effect of pregnancy on the population pharmacokinetics of levofloxacin in South Africans with rifampicin-resistant tuberculosis},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.01626-24}
}
EUVIMED